Catalog No. |
Product Name |
Information |
E3665 |
60% Yucca schidigera Extract |
60% Yucca schidigera Extract is extracted from Yucca schidigera. |
S7865 |
740 Y-P (PDGFR 740Y-P) |
740 Y-P (PDGFR 740Y-P, 740YPDGFR) is a cell-permeable phosphopeptide activator of PI3K. |
E8134 |
Y-26763 |
Y-26763 is a K+ channel opener and active metabolite of Y-27152. Y-26763 is an ATP-sensitive K+ (KATP) channel activator. |
S6390 |
Y-27632 |
Y-27632 is a selective ROCK1 and ROCK2 inhibitor with a Ki of 140 nM and 300nM in a cell-free assay, exhibits >200-fold selectivity over other kinases, including PKC, cAMP-dependent protein kinase, MLCK and PAK. |
S1049 |
Y-27632 2HCl |
Y-27632 2HCl is a selective ROCK1 and ROCK2 inhibitor with a Ki of 140 nM and 300nM in a cell-free assay, exhibits >200-fold selectivity over other kinases, including PKC, cAMP-dependent protein kinase, MLCK and PAK. |
S7516 |
Y-320 |
Y-320 is an orally active immunomodulator, and inhibits IL-17 production by CD4 T cells stimulated with IL-15 with IC50 of 20 to 60 nM. |
E7627 |
Y-33075 |
Y-33075 is a selective ROCK inhibitor derived from Y-27632, and is more potent than Y-27632, with an IC50 of 3.6 nM. |
S7935 |
Y-39983 Dihydrochloride |
Y-39983 (Y-33075)Dihydrochloride is a selective rho-associated protein kinase(ROCK) inhibitor with an IC50 of 3.6 nM. |
S0344 |
Y06036 |
Y06036 (Compound 6i) is a potent and selective inhibitor of BET with antitumor activity. Y06036 binds to the BRD4(1) bromodomain with Kd of 82 nM. |
S5321 |
Y15 |
Y15 (1,2,4,5-Benzenetetraamine tetrahydrochloride, FAK inhibitor 14) is a small-molecule FAK scaffolding inhibitor that directly inhibits FAK autophosphorylation in a dose- and time-dependent manner. |
S6752 |
Y16 |
Y16 is an inhibitor of G-protein-coupled Rho GEFs. It blocks the binding of LARG, a DBL-family Rho guanine nucleotide exchange factor, with Rho (Kd = 80 nM). |
E0840 |
Yakuchinone A |
Yakuchinone A, a natural product isolated from Alpinia oxyphylla Miquel (Zingiberaceae), has strong inhibitory effects on the synthesis of prostaglandins (PGs) and leukotrienes (LTs). |
E3618 |
Yam Extract |
Yam Extract is extracted from yam (Chinese yam), the rhizome of various species of genus Dioscorea opposita Thunb. (Dioscoreaceae). Yam contains mainly proteins, sugars, vitamins, fats, choline, amylase, iodine, iron, calcium, phosphorus, and other indispensable trace elements in the human body. The main pharmacological effects of yam are antioxidative, anti-aging, anti-tumor, and hypoglycemic. Yam also can enhance immunity. |
S5675 |
Yamogenin |
Yamogenin, a sapogenin found in fenugreek, inhibits lipid accumulation through the suppression of gene expression in fatty acid synthesis in hepatocytes. |
S9413 |
Yangonin |
Yangonin (Y100550) is a dienolide kavalactone originally found in Piper methysticum (kava plant) and exhibits neuroprotective, neuromodulatory, and antifungal activities. It activates cannabinoid (CB1) receptors and potentiates the effects of GABA-A receptors. |
F0366 |
YAP Rabbit mAb |
YAP,YAP1 |
S8164 |
YAP-TEAD Inhibitor 1 (Peptide 17) |
YAP-TEAD Inhibitor 1 (Peptide 17) is a YAP-TEAD protein-protein interaction inhibitor which has potential usage in treatment of YAP-involved cancers with IC50 of 25 nM. |
F1692 |
YAP1 (active) Rabbit mAb |
|
E5815 |
YB-3-17 |
YB-3−17 is a dual-target compound that effectively and selectively inhibits mTOR with an IC50 of 0.22 nM, while promoting GSPT1 degradation with an IC50 of 5 nM, leading to substantial tumor growth inhibition both in vitro and in vivo. It also exhibits significant antiproliferative activity in glioblastoma models. |
F1120 |
YB1 Rabbit mAb |
YB1,YB-1 |
E1985 |
YD23 |
YD23 is a PROTAC which induces the degradation of SMARCA2. It reduces chromatin accessibility in SMARCA4-deficient cells, affecting gene enhancers related to cell cycle and growth regulation, which leads to the downregulation of several cell cycle genes. It also selectively inhibits the growth of SMARCA4 mutant lung cancer cells in vitro. |
E8293 |
YD54 |
YD54 is a potent, selective and orally bioavailable PROTAC and a degrader of SMARCA2 with DC50 of 8.1 nM at 24 hours. It exhibits antitumor activity in SMARCA4-mutant lung cancer xenograft models and can be used in research on non-small cell lung cancer. |
E8294 |
YDR1 |
YDR1 is a potent, selective and orally bioavailable Cereblon-based PROTAC and a degrader of SMARCA2 with DC50 of 60 nM at 48 hours. It exhibits antitumor activity in SMARCA4-mutant lung cancer xenograft models and can be used in research on non-small cell lung cancer. |
E3344 |
Yeast extract |
Yeast Extract is extracted from yeast, which aids in boosting energy, supporting the immune system, and improving glucose sensitivity. |
S0022 |
YF-2 |
YF-2 is a highly selective, blood-brain-barrier permeable activator of histone acetyltransferase (HAT). In In vitro assays, YF-2 has activity versus CBP, PCAF, and GCN5 with EC50 of 2.75 μΜ, 29.04 μΜ and 49.3 μΜ, respectively. YF-2 also increases p300 activity. |
A4039 |
Yh32367 (Anti-4-1BB & HER2) |
Yh32367 is a humanized immunoglobulin G1 (IgG1) bispecific antibody targeting both the tumor-associated antigen (TAA) human epidermal growth factor receptor 2 (HER2; ErbB2; HER-2) and the costimulatory receptor 4-1BB (CD137; tumor necrosis factor receptor superfamily member 9; TNFRSF9). It exhibits potential immunostimulating and antineoplastic activities. M.W 200.52 kDa. |
S6715 |
YHO-13177 |
YHO-13177, a novel acrylonitrile derivative, is a potent BCRP/ABCG2 inhibitor. |
E4760 |
YJ1206 |
YJ1206 is an orally bioavailable, highly specific and potent degrader of CDK12/13 with an IC50 of 12.55 nM in VCaP cells. It increases DNA damage, induces apoptosis, and demonstrates robust anti-tumor activity in vivo. |
E8303 |
YJ9069 |
YJ9069 is a potent, selective and orally bioavailable PROTAC degrader of CDK12/CDK13. It inhibits proliferation in prostate cancer cells by inducing gene-length-dependent transcriptional elongation defects, leading to DNA damage, cell-cycle arrest, and significant tumor growth suppression in vivo. |
E0394 |
YK 3-237 |
YK-3-237, a SIRT1 activator, reduces acetylation of mutant p53 and inhibits the proliferation of triple-negative breast cancer cells. |
S0051 |
YKL 06-061 |
YKL 06-061 is a potent and selective salt-inducible kinase (SIK) inhibitor with IC50 of 6.56 nM, 1.77 nM and 20.5 nM for SIK1, SIK2 and SIK3, respectively. |
S9646 |
YKL-05-099 |
YKL-05-099 is an inhibitor of salt-inducible kinase (SIK) with IC50 of ~10 nM, ~40 nM and ~30 nM for SIK1, SIK2 and SIK3, respectively. |
S8863 |
YKL-5-124 |
YKL-5-124 is a potent, selective and covalent CDK7 inhibitor with an IC50 of 9.7 nM, 1300 nM and 3020 nM for inhibiting CDK7/Mat1/CycH, CDK2 and CDK9 respectively. It displays biochemical and cellular selectivity for CDK7 over CDK12/13. |
S0282 |
YL 0919 |
YL0919, a novel structure compound, exerts dual effect on the serotonergic system, as both 5-hydroxytryptamine receptor 1A (5-HT1A) agonist and 5-HT uptake blocker, showing remarkable antidepressant effects in animal models. |
S6607 |
YL-109 |
YL-109 is a novel antitumor agent that has ability to inhibit breast cancer cell growth and invasiveness in vitro and in vivo. |
E2371 |
YLF-466D |
YLF-466D is an AMPK activator that inhibits platelet aggregation with IC50 of 84 μM. |
S5764 |
YM 90709 |
YM 90709 is a novel IL-5 inhibitor which selectively blocks the binding of IL-5 to the IL-5 receptor (IL-5R). |
E8129 |
YM022 |
YM022 is a highly potent, selective and orally active gastrin/cholecystokinin (CCK)-B receptor (CCK-BR) antagonist. YM022 shows the Ki values of 68 pM and 63 nM for CCK-B and CCK-A receptor, respectively. YM022 can inhibit gastrin-induced gastric acid secretion and histidine decarboxylase activation in vivo. |
S1219 |
YM201636 |
YM201636 is a selective PIKfyve inhibitor with IC50 of 33 nM, less potent to p110α and insensitive to Fabl (yeast orthologue). YM-201636 suppresses the growth of liver cancer via the induction of autophagy. |
S6678 |
Yoda1 |
Yoda1 acts as an agonist for both human and mouse Piezo1(EC50 of 17.1 and 26.6 μM for mouse and human). Yoda1 activates purified Piezo1 channels in the absence of other cellular components. |
S2373 |
Yohimbine HCl |
Yohimbine (Antagonil) has been used as a mydriatic and in the treatment of impotence. It is also alleged to be an aphrodisiac. |
E0138 |
YQ128 |
YQ128 is a selective inhibitor of NLRP3 with an IC50 of 0.30 µM.
|
E0785 |
YS-49 |
YS-49 is a PI3K/Akt (a downstream target of RhoA) activator, to reduce RhoA/PTEN activation in the 3-methylcholanthrene-treated cells, inhibits angiotensin II (Ang II)-stimulated proliferation of VSMCs via induction of heme oxygenase (HO)-1, also is an isoquinoline compound alkaloid, has a strong positive inotropic action through activation of cardiac β-adrenoceptors. |
F2764 |
YTHDC2 Rabbit mAb |
|
F2505 |
YTHDF1 Rabbit mAb |
|
F2153 |
YTHDF2 Rabbit mAb |
|
F2793 |
YTHDF3 Rabbit mAb |
|
S6193 |
YUM70 |
YUM70 is a potent inhibitor of glucose-regulated protein 78 (GRP78) inhibitor with an IC50 of 1.5 μM. YUM70 induces endoplasmic reticulum (ER) stress-mediated apoptosis in pancreatic cancer.Although YUM70 inhibits GRP78 enzymatic activity, it increases the expression of GRP78 by increasing the chaperone translation mechanism. |
E8288 |
YW-N-7 TFA |
YW-N-7 TFA is a PROTAC that targets the inhibition and degradation of RET with a DC50 of 88 nM. It also exhibits antitumor activity in a KIF5B-RET-driven xenograft mouse model. |
E8287 |
YX0597 |
YX0597 is a potent and selective CDK9 PROTAC degrader that reduces RNA polymerase II S2 phosphorylation and MCL1 expression in GA0518 and AGS cells. It effectively inhibits GEAC cell growth, including radiation-resistant tumors, and suppresses tumor proliferation, metastasis, and cancer stem cells. |
E8302 |
YX968 |
YX968 is a potent, rapid, and selective PROTAC dual degrader of HDAC3/8 with DC50 values of 1.7 nM and 6.1 nM, respectively. It promotes apoptosis and kills cancer cells with a high potency in vitro and can be used in cancer research. |
F1166 |
YY1 Rabbit mAb |
YY1 Rabbit mAb recognizes endogenous levels of total YY1 protein. |
S7487 |
YYA-021 |
YYA-021 is a CD4-mimic HIV entry inhibitor, competitively inhibiting the interaction between gp120 and CD4. |